Georgetown University - Developmental Therapeutics Review - Q4 2010

Georgetown University – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Georgetown University – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Georgetown University.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Georgetown University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of Georgetown University’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in Georgetown University’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate Georgetown University’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of Georgetown University in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with Georgetown University.
- Avoid Intellectual Property Rights related issues. SHOW LESS READ MORE >

List of Tables
List of Figures
Georgetown University Snapshot
Georgetown University Overview
Key Information
Key Facts
Georgetown University – Research and Development Overview
Key Therapeutic Areas
Georgetown University – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Georgetown University – Pipeline Products Glance
Georgetown University – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Georgetown University Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Georgetown University–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Georgetown University – Drug Profiles
Kefir
Product Description
Mechanism of Action
R&D Progress
Kefir
Product Description
Mechanism of Action
R&D Progress
Lactobacillus (L.) casei
Product Description
Mechanism of Action
R&D Progress
Lexiva + Norvir + Epzicom
Product Description
Mechanism of Action
R&D Progress
Rituxan
Product Description
Mechanism of Action
R&D Progress
Sustiva + Epzicom
Product Description
Mechanism of Action
R&D Progress
Albumin
Product Description
Mechanism of Action
R&D Progress
Albumin
Product Description
Mechanism of Action
R&D Progress
Carnosine
Product Description
Mechanism of Action
R&D Progress
Cisplatin
Product Description
Mechanism of Action
R&D Progress
Lapatinib + Capecitabine
Product Description
Mechanism of Action
R&D Progress
mFOLFOX6 + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Modified FOLFOX6 + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Ofatumumab + Bendamustine
Product Description
Mechanism of Action
R&D Progress
pemetrexed
Product Description
Mechanism of Action
R&D Progress
sunitinib + capecitabine
Product Description
Mechanism of Action
R&D Progress
Temozolomide + ABT-888
Product Description
Mechanism of Action
R&D Progress
Bendamustine + Lenalidomide
Product Description
Mechanism of Action
R&D Progress
Bendamustine + Lenalidomide + Rituximab
Product Description
Mechanism of Action
R&D Progress
Bosentan
Product Description
Mechanism of Action
R&D Progress
Enbrel_
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + capecitabine
Product Description
Mechanism of Action
R&D Progress
LErafAON
Product Description
Mechanism of Action
R&D Progress
Georgetown University – Pipeline Analysis
Georgetown University – Pipeline Products by Therapeutic Class
Georgetown University Pipeline Products By Target
Georgetown University – Pipeline Products by Route of Administration
Georgetown University – Pipeline Products by Molecule Type
Georgetown University – Recent Pipeline Updates
Georgetown University – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Georgetown University, Deals Volume Summary, 2004 to YTD 2010
Georgetown University, Deals Summary By Region, 2004 to YTD 2010
Georgetown University, Deals Summary, 2004 to YTD 2010
Georgetown University Detailed Deal Summary
Samaritan Pharmaceuticals Extends Research Agreement With Georgetown University
Samaritan Pharmaceuticals Expands Agreement With Georgetown University
Licensing Agreements
Samaritan Pharmaceuticals Enters Into Licensing Agreement With Georgetown University
Samaritan Pharmaceuticals Enters Into Licensing Agreement With Georgetown University
Samaritan Pharmaceuticals Enters Into Licensing Agreement With Georgetown University
Samaritan Pharmaceuticals Enters Into Licensing Agreement With Georgetown University
Samaritan Enters Into Licensing Agreement With George Town University
Samaritan Pharmaceuticals Enters Into Licensing Agreement With Georgetown University
Samaritan Pharmaceuticals Enters Into Licensing Agreement With Georgetown University
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer